The qualification of a PBPK modeling system for the prediction of drug interactions encompasses in general the qualification of the software platform, the PK model for the new drug, and validation versus clinical interaction data. The following sections address these topics.
Evofosfamide PK model qualification
The PBPK model describing the PK of evofosfamide was developed using data from a Phase I monotherapy dose-escalation study in patients with solid tumors (NCT00495144). Concentration time data were grouped according to infusion duration. Dose levels closest to the target dose levels of 300 mg/m² and 340 mg/m² were used, as follows: After refinement of the model, the data from across the above dose levels, and from both week 1 (first infusion) and week 3 (third infusion), were properly predicted by the PBPK model. That is, the final model predictions fitted the observed data well, or were slightly higher than the clinically observed concentrations. Some overprediction is acceptable since it fits with the conservative approach to estimate the interaction potential of evofosfamide as perpetrator. The overall purpose of the model is not to The results show that the evofosfamide PK model reasonably well predicts the PK observed clinically at dose levels of 240 mg/m², 480 mg/m², and 575 mg/m². This applies to both patients with 30 min as well as those with 60 min scheduled infusion duration, and for data obtained in week 1 as well as week 3.
Due to the short half-life of evofosfamide, there is no accumulation after weekly administration, and the concentration time profiles of the two weeks are in the same concentration range, respectively.
The evofosfamide PK model was also validated against data from a second, independent clinical study.
Due to the toxicity of evofosfamide, no study in healthy volunteers could be conducted Simulated and observed plasma concentration time profiles of evofosfamide given as intravenous infusion of 340 mg/m² over 30 min. 100 subjects were simulated, the 5 th and 95 th percentile as well as the mean concentration-time profiles are shown (symbols joined by lines). The individual observed clinical data of the combination study (NCT00743379) are plotted as a function of time (circles). Overlay plots are shown for week 1 (top) and week 3 (bottom).
Precise quantification versus "lower-bound" approach
In general, for a precise quantification of an actual interaction, a qualification of an interaction model by comparison of the predicted interaction with results of a clinical interaction study adds confidence.
However, this is not necessary and not possible for the questions discussed here. It is not necessary, because the worst-case approach taken gives only a lower bound. However, this is sufficient to exclude the interaction potential in the cases discussed in the main text body. A clinical interaction study in healthy volunteers was not possible due to the known genotoxicity and the side effect profile of evofosfamide.
